Clinical Trials
12 trialsNCT06031688 2026-05-05
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Recruiting
NCT05782361 2026-04-24
POTENT
Institute of Cancer Research, United Kingdom
Phase 1 Active not recruiting
NCT02864992 2026-04-13
VISION
EMD Serono
Phase 2 Active not recruiting
NCT06083857 2026-03-11
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03940703 2026-02-27
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
EMD Serono
Phase 2 Active not recruiting
NCT06106802 2026-02-23
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Samsung Medical Center
Phase 2 Recruiting
NCT06908993 2025-12-17
COMET
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Recruiting
NCT04739358 2023-10-18
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Criterium, Inc.
Phase 1/2 Terminated
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT03492437 2023-08-07
Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03531762 2023-07-28
Effect of a Proton Pump Inhibitor on the PK of Tepotinib
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT01982955 2022-11-08
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed